Maintenance immunotherapy following chemotherapy may improve survival in advanced urothelial cancer. In the phase III JAVELIN Bladder 100 trial, patients treated with the PD-L1 inhibitor avelumab plus best supportive care after first-line chemotherapy had significantly longer overall survival and progression-free survival than those who received best supportive care alone.

©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.